Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
i can see a real synergy combining the two companies. nagogenics expect their product to be in clinic in 2025. not sure what their financial state is but we seem to have financed them to that in clinic stage. the deal allows them to still have enough skin in the company should this go commercial. nigel has always said he was open to an acquisition. this looks the best fit he could have achieved. it also broadens the range of n4p with a ready made almost ready to go product. biotech has suffered all round this year with the big pharmaceuticals cutting back on expenditure. the word is that that is changing for the coming year. this looks like a better investment than money doing nothing, although they raised all the cash to buy this, but the cash they do have should see them through to 2025, as they both appear to have minimal expenditure requirements. a much needed extra string to the bow. forget the sp, this is **** or bust now
There is great potential with N4P's Nuvec as an alternate delivery system. We know that it is proven to be similar to commercially available molecules (AZ and Roche) but this deal raises quite a few questions:
* At Companies House Nanogenics states Ryboquin Ltd as a person with significant control as of 4th September / updated on 27th Sept.
* Who are they / what do they bring to the party. Zero employees at Companies House.
* Why are N4P not spending every possible resource on Nuvec following the successful oral delivery announcement?
* Is the deal announced today complementary to Nuvec / in support of Nuvec or is it a new avenue N4P is now exploring?
* 2 weeks ago we were told that the "Cash position remains strong" and "We believe in being prudent with our cash resources as far as possible whilst continually progressing our pre-clinical proof of concept data package with ongoing refinements to meet potential collaborators' requirements. In addition, we consider that focussing on our own product development (whether in partnership or on our own) for the continued development of Nuvec® is the right strategy for a company of our size. Nuvec® remains an exciting technology with huge potential as an alternate system for the delivery of nucleic acid-based therapies."
Come on Nigel and N4P we need more transparency. The current situation is not good enough.
As investors we can see the potential here.....
Good luck, Brighty
Wow raising money to buy into another business, while his own business is struggling? Maybe he has given up with Nuvec and has his eye on something else? All very strange, only person benefiting here is the swindler Nigel! All for one and one for all!
The thing that annoys me is the last placement was supposed to be for this sort of investment. Not raise again at a silky level. Let's see some results and get the price up. Awful CEO
Not only is it’s principal target a huge market, helping patients recover glaucoma surgery, Nigel sees the potential in Lung and liver disease. Cant accuse him of being short sighted. Might actually top up this time when it goes sub 1p
Actually it does sound bloody amazing, but then so did Nuvec. Thats one thing about N4p its better than doing open university in medical procedures!
It may be a great buy, but its cost us 50% of the company to do it. Requires an explanation Nige. Rationale not in N4p vocabulary.
It's a good aquasition but not happy with the placement.
Whether news is good or bad, any news from n4p is followed by a drop in SP.
That will pay for Nigel to live in the tropics for another 6 months !!!
CROOK
just focus on n4p we don't need more **** to drag hs down, what a complete joke
Seems someone knew there is an RNS this morning. So corrupt
Well they certainly dropped the bid. Thats a crazy price. Need something from the BOD
That one this morning at 8.57am was mine and it was a buy not a sell. Nice low price to buy in at. Which way will it go? Well let's see....
I'm definitely looking for a lot more but i would be happy to see 2.9 in the interim
Good luck to you but most on here are looking for it to go much much higher than 2.90, pending business development / news.
Buy some more msuk, then we may stand a chance of getting there quicker :)
Putting my neck on the line c2.90 on the cards
You can't possibly know it was the same person, unless it was you. I guess you are matching the trade volumes, but that is hardly scientific proof.
Always amazes me how people buy in one day and sell the next day at a loss.
One person bought in yesterday in the morning and sold in the afternoon at a £97 loss.
Very strange strategy.